Wegovy vs Ozempic

Summary: Wegovy and Ozempic are the same molecule, semaglutide, sold under two brand names: Wegovy is FDA approved for weight management at up to 2.4 mg (and 7.2 mg as of 2026), Ozempic is approved for type 2 diabetes at up to 2 mg.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: Wegovy and Ozempic are the same drug, semaglutide, made by the same company, Novo Nordisk. The difference is the label on the box and the maximum dose. Wegovy is FDA approved for chronic weight management and titrates up to 2.4 mg weekly, with a new high-dose 7.2 mg version (Wegovy HD) approved in March 2026 ^[4]. Ozempic is FDA approved for type 2 diabetes and stops at 2 mg weekly ^[2]. Everything else, the molecule, the mechanism, the side effect profile, the injection device, is essentially identical.

What this means in practice: which brand you get depends less on biology and more on what your insurance will pay for and what diagnosis is on your chart.

Same molecule, two FDA labels

Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone glucagon-like peptide-1, which prompts insulin release when blood sugar rises, slows gastric emptying, and signals fullness in the brain ^[5]. Novo Nordisk runs separate development programs for the same molecule because the US regulatory system requires separate approvals for separate indications. So semaglutide was approved twice.

Wegovy carries a few extra labeled uses Ozempic does not have: pediatric obesity (ages 12 and up), cardiovascular risk reduction in adults with obesity or overweight plus existing heart disease, and treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) ^[1][5]. Ozempic has its own extras Wegovy does not have: kidney disease progression in adults with type 2 diabetes and chronic kidney disease ^[2].

Why Wegovy is the better choice for weight loss

The mechanism is identical, so why does Wegovy win for weight loss? Two reasons. The first is the dose ceiling. Wegovy titrates to 2.4 mg weekly, while Ozempic stops at 2 mg ^[1][2]. With the 2026 Wegovy HD approval, the high-dose Wegovy goes all the way to 7.2 mg weekly ^[4]. Semaglutide's appetite-suppression effect is dose dependent, so more milligrams pushes more weight off.

The second reason is the trial program. Wegovy's approval rests on the STEP trials, which enrolled adults with obesity (or overweight plus a weight-related condition) and measured weight loss as the primary endpoint. In STEP 1, adults on 2.4 mg semaglutide lost an average 14.9% of body weight over 68 weeks compared with 2.4% on placebo ^[3]. STEP UP, the trial supporting Wegovy HD, showed roughly 21% body weight reduction at 7.2 mg over 72 weeks. Ozempic's clinical data is mostly built around hemoglobin A1c reduction in type 2 diabetes patients, where weight loss is a welcome side benefit but not the headline.

In the diabetes trials, people on 2 mg Ozempic lost around 14 lbs (6.4 kg) over 40 weeks. That is real, but it is not the 35 lbs (16 kg) the 2.4 mg Wegovy dose produces over 68 weeks in non-diabetic adults ^[5]. The gap reflects the higher dose, the longer duration, and the fact that people without diabetes tend to lose more weight on the same molecule than people with diabetes do.

When off-label Ozempic might be cheaper

Here is where the brand split gets interesting. Some clinicians prescribe Ozempic off-label for weight loss, particularly when a patient has obesity but no type 2 diabetes diagnosis. The reason is almost always money.

Most US commercial insurance plans do not cover Wegovy. They categorize anti-obesity medications as lifestyle drugs, which is a coverage carve-out that dates back decades. The same plans usually do cover Ozempic, because type 2 diabetes is a covered medical diagnosis. If a patient with a BMI of 32 and an HbA1c of 6.4 (prediabetes) walks into a clinic, the conversation about whether to chart Ozempic or Wegovy is largely a conversation about which prescription their plan will fill.

Off-label Ozempic for weight loss has real downsides:

• The max dose is 2 mg, not 2.4 or 7.2 mg, so the weight loss ceiling is lower.
• Insurance has gotten stricter about reviewing Ozempic prescriptions that lack a diabetes diagnosis, with some plans denying coverage if the patient's chart does not document type 2 diabetes or prediabetes.
• The titration schedule and dosing are not optimized for weight management, since the clinical trials were diabetes trials.

Cash pricing has narrowed the gap. As of late 2025, Novo Nordisk introduced direct cash pricing through NovoCare Pharmacy. New self-pay patients can get the first two months of Wegovy 0.25 mg or 0.5 mg (or Ozempic) at $199 per month, with the standard cash price dropping to $349 per month afterward ^[5]. The list price without any discount is around $1,350 to $1,400 per month for either brand, so the cash-pay program is a meaningful discount, but still well above what insurance copays look like when coverage exists.

The cash price changes constantly. Check NovoCare and the manufacturer site for current pricing before quoting any number out loud to a patient.

Switching between Wegovy and Ozempic

People switch in both directions, and the logistics are usually straightforward because the active ingredient is the same.

Ozempic to Wegovy. Common when a patient who has been on Ozempic for diabetes (with weight loss as a benefit) wants to push past the 2 mg dose ceiling, or when their diagnosis no longer supports Ozempic coverage but they qualify for Wegovy under their plan. The standard approach is to match the dose at the switch point. Someone on 1 mg Ozempic weekly switches to 1 mg Wegovy weekly, then resumes the Wegovy titration schedule on the way to 2.4 mg (or 7.2 mg). No washout period is needed because the molecule is identical and the half-life is unchanged.

Wegovy to Ozempic. Less common but happens when a patient develops type 2 diabetes during Wegovy therapy, or when insurance coverage flips. The dose match works in reverse. Someone on 2.4 mg Wegovy who needs to switch to Ozempic gets dialed back to the 2 mg Ozempic ceiling, since Ozempic is not labeled for higher doses. The semaglutide is the same, the brand and indication are different.

Switching from compounded semaglutide. The 2024 to 2025 semaglutide shortage produced a large compounded semaglutide market. Now that brand supply has stabilized and the FDA has tightened compounding rules, many patients are converting from compounded vials to branded Wegovy or Ozempic pens. The dose conversion is one-to-one on milligrams. If you were on 1.7 mg compounded weekly, you switch to a Wegovy 1.7 mg pen or stay on Ozempic in the 1 to 2 mg range depending on your prescription.

Side effects: nearly identical, slightly worse at higher doses

Because the molecule is the same, the side effect profile is the same. The intensity scales with dose. Nausea is the headline complaint and the most common reason people quit early. In the trials, nausea occurred in 44% of people on Wegovy 2.4 mg compared with 20% of people on Ozempic 1 mg ^[5]. That gap is mostly the dose gap. At matched doses the rates are similar.

Other common GI complaints (diarrhea, vomiting, constipation, abdominal pain) follow the same pattern. The titration schedule exists to manage these. Both Wegovy and Ozempic start at 0.25 mg weekly for four weeks, then step up. People who push the schedule faster than the label specifies almost always quit early because the GI side effects overwhelm them.

The boxed warning is also identical. Both labels carry the warning about thyroid C-cell tumors based on rodent studies. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use either drug ^[1][2]. Other label warnings (pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, kidney injury during dehydration, diabetic retinopathy progression) apply equally to both.

Devices: single-dose pen vs multi-dose pen

A small but real practical difference. Wegovy ships as a single-use disposable pen at a single strength per pen. You attach a needle, press the button, and throw the pen out. Each box contains four pens for one month of doses.

Ozempic ships as a multi-use pen that lasts roughly four weeks per pen, with a dial that lets you select the dose. The same pen can deliver multiple doses, and a single pen covers most of the lower-dose titration steps. Some people prefer the Ozempic pen because there is less plastic to throw out and the device is easier to travel with. Others prefer the Wegovy pen because the dose is preset and there is no dial to misread.

Both pens use the same standard pen needles. Both inject subcutaneously into the abdomen, thigh, or upper arm. Both are dosed once weekly on the same day of the week.

What about oral semaglutide?

Both brands now have oral versions. Wegovy tablets at 25 mg once daily got FDA approval based on the OASIS 4 trial, which showed about 16.6% weight loss over 64 weeks in adults with obesity (without diabetes) ^[5]. Ozempic tablets, formerly known as Rybelsus, are approved at 7 mg and 14 mg once daily for type 2 diabetes, with a newer R2 formulation at 1.5, 4, and 9 mg.

The oral versions absorb poorly compared with the injection. You have to take them on an empty stomach with no more than 4 ounces of water and wait at least 30 minutes before eating, drinking, or taking other oral medications. Miss that window and absorption drops significantly. The injection bypasses all of this, which is why the weekly shot remains the default for most patients.

Frequently asked questions

Is Wegovy the same as Ozempic?

Both contain semaglutide and are made by Novo Nordisk. They differ in FDA-approved use (Wegovy for weight management, Ozempic for type 2 diabetes) and maximum dose (Wegovy 2.4 mg or 7.2 mg, Ozempic 2 mg).

Is ozempic vs wegovy a meaningful difference for weight loss?

For weight loss, Wegovy is the better choice because the higher max dose produces more weight loss and the trials measured weight loss as the primary endpoint. Ozempic can produce weight loss off-label but caps at 2 mg.

What is the wegovy vs ozempic cost difference?

List prices are similar, around $1,350 per month. Cash-pay through NovoCare is $349 per month for either, after a $199 intro for the first two months. Insurance coverage is the main divider: Wegovy is rarely covered, Ozempic usually is for diabetes.

Is semaglutide vs wegovy the same medication?

Yes. Semaglutide is the active ingredient. Wegovy is one brand of semaglutide. Ozempic is another. Rybelsus and the new Wegovy tablets are oral semaglutide. Compounded semaglutide is also semaglutide.

What is the difference between wegovy vs semaglutide?

There is no chemical difference. Wegovy is the brand name for semaglutide approved for weight management. When people say "semaglutide" they may mean Wegovy, Ozempic, Rybelsus, or a compounded version. The molecule is the same.

Can I switch from Ozempic to Wegovy without a break?

Yes. Match your current Ozempic dose to the same Wegovy dose, then resume the Wegovy titration. No washout is needed because the molecule is identical and the half-life is unchanged.

Why do some doctors prescribe Ozempic off-label for weight loss?

Insurance coverage. Most commercial plans cover Ozempic for diabetes but exclude weight loss drugs. Off-label Ozempic for weight loss may be the only affordable path for some patients, though the 2 mg max limits results.

How does semaglutide vs ozempic vs wegovy compare for cardiovascular risk?

All three are the same molecule. Ozempic is labeled for cardiovascular risk reduction in adults with type 2 diabetes and known CVD. Wegovy is labeled for cardiovascular risk reduction in adults with obesity or overweight and existing CVD (with or without diabetes).

What is Wegovy HD?

Wegovy HD is the 7.2 mg dose of semaglutide, approved by the FDA in March 2026. It pushes the maximum weekly dose above the prior 2.4 mg ceiling and produced about 21% body weight reduction over 72 weeks in the STEP UP trial.

Does Medicare cover Wegovy or Ozempic?

Medicare Part D generally does not cover weight loss drugs, which excludes Wegovy for most beneficiaries. Ozempic is typically covered under Part D for type 2 diabetes with prior authorization. Recent legislative changes around obesity drug coverage are pending.

What this article does not cover

This is the comparison between Wegovy and Ozempic, the two semaglutide brands. Semaglutide vs tirzepatide (Mounjaro and Zepbound) is a separate decision with different evidence, and that comparison has its own dedicated page. So does the specific question of off-label Ozempic dosing for weight loss, the compounded semaglutide market, and the detailed cost breakdown by insurance plan. Use the search or the comparisons section to find them. The core fact here is that Wegovy and Ozempic are the same drug, and your choice between them is driven by your diagnosis, your insurance, and your weight loss target.